A phase 2, open label, multicenter, single arm study of tocilizumab on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia (TOCIVID-19 trial): Statistical analysis plan

Paolo Chiodini, Laura Arenare, Maria Carmela Piccirillo, Francesco Perrone, Ciro Gallo, Paolo Chiodini, Laura Arenare, Maria Carmela Piccirillo, Francesco Perrone, Ciro Gallo

Abstract

Background: Tocilizumab, an IL-6 receptor antagonist, was suggested as a possible treatment of severe or critical COVID-19 pneumonia in a small Chinese study. The TOCIVID-19 trial evaluates efficacy and tolerability of tocilizumab in the treatment of patients with severe or critical COVID-19 pneumonia.

Methods: TOCIVID-19 is an academic multicenter, single-arm, open-label, phase 2 study. All the patients are being offered a single shot of 8 mg/kg of Tocilizumab (up to a maximum of 800 mg), with an eventual second administration at the discretion of the Investigator. A companion prospective cohort, added to corroborate internal validity, includes either patients not eligible for phase 2 or subjects eligible for phase 2 but exceeding the planned sample size. 14- and 30-days lethality rates are the two co-primary endpoints in the intention-to-treat (ITT) population. Secondary objectives are to evaluate mortality and clinical improvement in the modified-ITT population of subjects who received the drug. Details of the methodological and statistical approaches are reported here reflecting the amendments impelled by the continuously increasing knowledge on COVID-19 progression and challenges in data collection.

Conclusion: This paper provides details of planned statistical analyses for TOCIVID19 trial to reduce the risk of reporting bias and increase validity of the study findings.TOCIVID-19 trial is registered in the EudraCT database with number 2020-001110-38 and in clinicaltrials.gov with ID NCT04317092.

Keywords: COVID-19 pneumonia; Phase 2 trial; Statistical analysis plan; Tocilizumab.

Conflict of interest statement

PC, LA and CG have no competing interests. FP and MCP coordinate three academic clinical trials in oncology, promoted by the Istituto Nazionale Tumori di Napoli, that are supported by Roche (clilnicaltrials.gov id: NCT01706120, NCT01802749, NCT02633189).

© 2020 The Authors.

References

    1. Boccia S, Ricciardi W, Ioannidis JPA. What other countries can learn from Italy during the COVID-19 Pandemic. JAMA Intern Med Published online April 7, 2020.
    1. Pasquariello P., Stranges S. Excess mortality from COVID-19: a commentary on the Italian experience. Int. J. Publ. Health. 2020;65(5):529–531.
    1. Xiaoling Xu, Mingfeng Han, Tiantian Li et al. Effective Treatment of Severe COVID-19 Patients with Tocilizumab. ChinaXiv: 202003.00026v1, now published in PNAS 10.1073/pnas.2005615117.
    1. Xiaoling Xu (PI). A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19). Registration number on ChiCTR: ChiCTR2000029765 of February 13 2020.
    1. Gamble C., Krishan A., Stocken D. Guidelines for the content of statistical analysis plans in clinical trials. J. Am. Med. Assoc. 2017;318(23):2337–2343.
    1. Giorgi Rossi P., Ferroni E., Spila Alegiani S., Leoni O., Pitter G., Cereda D., Marino M., Pellizzari M., Sultana J., Trifirò G., Massari M., the ITA-COVID19 working group Survival of hospitalized COVID-19 patients in Northern Italy: a population-based cohort study by the ITA-COVID19 Network. medRxiv. 2020 doi: 10.1101/2020.05.15.20103119.
    1. International council on harmonization of technical requirements for registration of pharmaceuticals for human use. Addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials E9(R1) available at.
    1. Schulz K.F., Altman D.G., Moher D., CONSORT Group CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332.
    1. Lin D.Y. Non-parametric inference for cumulative incidence functions in competing risks studies. Stat. Med. 1997;16(8):901–910.
    1. Bernasconi D.P., Rebora P., Iacobelli S. Survival probabilities with time-dependent treatment indicator: quantities and non-parametric estimators. Stat. Med. 2016;35:1032–1048.
    1. Poguntke I., Schumacher M., Beyersmann J., Wolkewitz M. Simulation shows undesirable results for competing risks analysis with time-dependent covariates for clinical outcomes. BMC Med. Res. Methodol. 2018;18:79.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe